India's Ranbaxy is interested in bidding for German chemical and pharmaceutical company Merck KGaA's generic-drug business.
But Ranbaxy may face competition from larger rivals Teva and Novartis AG, analysts said.
Teva last year bought U.S. generic-drug maker Ivax Corp. for $7.6 billion to keep the top spot, while Basel, Switzerland- based Novartis paid $8.3 billion for Hexal AG and Eon Labs Inc. in 2005.
More at Bloomberg
No comments:
Post a Comment